Skip to main
VERU
VERU logo

Veru (VERU) Stock Forecast & Price Target

Veru (VERU) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 38%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Veru Inc has demonstrated a robust cash position and notable financial performance, highlighted by net revenues of $16.9 million, reflecting a 4% year-over-year growth that exceeded projections and showcased the company's ability to generate revenue efficiently. The positive outlook is further supported by the anticipated reporting of topline data from the Phase 2b sarcopenic obesity trial in January 2025, which could facilitate partnerships for the enobosarm program aimed at obesity treatment. Additionally, the ease of administration of enobosarm as an oral drug offers a competitive advantage over alternatives requiring intravenous administration, potentially enhancing its market appeal and driving future growth.

Bears say

Veru Inc. is facing significant negative outlook factors, primarily due to a drastic reduction in its workforce from 210 to 22 employees following the sale of its UK and Malaysian subsidiaries, indicating potential operational instability. Furthermore, the company's drug, enobosarm, is subject to multiple investment risks including the possibility of failure in clinical trials for obesity treatment, challenges in obtaining regulatory approval, and uncertainties surrounding its commercial success related to reimbursement and competition. Additionally, concerns regarding dilution risk further complicate the investment landscape, exacerbating doubts about the company's financial health and growth prospects.

Veru (VERU) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 38% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Veru and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Veru (VERU) Forecast

Analysts have given Veru (VERU) a Buy based on their latest research and market trends.

According to 8 analysts, Veru (VERU) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Veru (VERU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.